What is the etiology of POEMS syndrome and how should it be managed?

POEMS Syndrome: Etiology and Management

POEMS syndrome is caused by an underlying clonal plasma cell neoplasm (almost always lambda-restricted) that produces elevated vascular endothelial growth factor (VEGF), which drives the multisystem manifestations of the disease. 1

Etiology

The syndrome results from a monoclonal plasma cell disorder that secretes pathogenic factors, particularly VEGF, leading to the characteristic clinical features 1. The plasma cell clone is typically:

• Lambda light chain restricted (almost always λ, not κ) 1
• Low tumor burden compared to multiple myeloma 2, 3
• Associated with sclerotic bone lesions or Castleman disease 1

The elevated VEGF appears to be the key mediator of the paraneoplastic features, though the exact pathogenic mechanisms remain incompletely understood 2, 3.

Diagnostic Criteria

Diagnosis requires 3 major criteria (including both mandatory criteria) plus ≥1 minor criterion 1:

Major Criteria (2 mandatory):

• Polyradiculoneuropathy (mandatory)
• Clonal plasma cell disorder (mandatory)
• Elevated VEGF
• Sclerotic bone lesions
• Castleman disease

Minor Criteria:

• Organomegaly
• Endocrinopathy
• Skin changes
• Papilledema
• Extravascular volume overload
• Thrombocytosis

Essential Workup

Perform the following to establish diagnosis and extent of disease 1:

• Iliac crest bone marrow biopsy/aspirate
• Serum and urine immunofixation with free light chains
• Serum VEGF levels
• Whole body X-rays and FDG-PET scan
• CT abdomen/pelvis
• Pulmonary function tests
• Cardiac ultrasound
• Endocrine laboratory panel

Treatment Algorithm

For Localized Disease (No Bone Marrow Involvement)

Radiation therapy is the treatment of choice 1:

• Achieves 97% 4-year overall survival 1
• Results in 52% 4-year failure-free survival 1
• Provides long-lasting responses in localized disease 1

For Disseminated Disease (Bone Marrow Involvement)

Systemic therapy targeting the plasma cell clone is mandatory 1. Treatment selection depends on transplant eligibility:

Transplant-Eligible Patients:

High-dose melphalan with autologous stem cell transplant (ASCT) is preferred 1, 2, 3:

• Achieves 100% clinical improvement rates 1
• Provides durable remissions without maintenance 4
• Patients achieving complete hematologic response have 88% progression-free survival 4
• 10-year overall survival approaches 80% 4

Induction regimens before ASCT:

• Melphalan-dexamethasone: 81% hematologic response, 100% neurologic improvement 1
• Lenalidomide-dexamethasone: Majority respond 1, 2, 3
• Cyclophosphamide-dexamethasone: 50% clinical improvement 1

Transplant-Ineligible Patients:

Lenalidomide-dexamethasone is the preferred option 2, 3, 5:

• Provides durable hematologic and neurological responses 6
• Well-tolerated in this population 5

Alternative regimens:

• Melphalan-dexamethasone (low-dose conventional) 2, 3
• Cyclophosphamide-dexamethasone 1
• Corticosteroids alone (temporizing only) 1, 2

Critical Caveats - Avoid Neurotoxic Agents

Thalidomide and bortezomib are NOT recommended as first-line therapy 1:

• Both can exacerbate pre-existing polyneuropathy 1, 2, 3
• Thalidomide: Not recommended first-line due to neuropathy risk 1
• Bortezomib: Almost all respond but consider neurotoxicity 1
• Reserve these only when benefits clearly outweigh risks 2, 3

Bevacizumab should be avoided - reduces VEGF but associated with several death reports 1

Emerging Therapies

Daratumumab combinations appear promising based on case series 2, 3, though more data are needed.

Response Monitoring

Expect significant treatment lag 1:

• Maximum neurologic response: 2-3 years after successful therapy 1
• Optimal FDG-PET response: May lag 6-12 months 1
• Monitor VEGF levels, hematologic parameters, and neurologic function serially

Adjuvant Considerations

• Large bone lesions may require radiation 6 months post-chemotherapy 1
• Comprehensive supportive care is essential: manage endocrinopathy, thrombotic risk, neuropathic pain, and infection prophylaxis 2, 3, 5

Key Prognostic Factors

Risk stratification is clinical, not molecular 2, 3:

• Low serum albumin
• Advanced age
• Pleural effusion
• Pulmonary hypertension
• Reduced eGFR

Early diagnosis and prompt treatment initiation improve overall survival and quality of life 2, 3, 5.